打开APP

Lilly实验药物solanezumab有希望治疗阿尔兹海默病

  1. Lilly
  2. solanezumab
  3. 阿尔兹海默病

来源:生物谷 2013-03-04 14:15

2013年1月21日讯 /生物谷BIOON/ --Lilly公司正在实验中的药物solanezumab可能有望治疗阿尔兹海默病,这种药物能够清除淀粉样蛋白,这是一种在阿尔兹海默病患者大脑细胞中广泛存在的蛋白质。但是截止2012年,这种药物的两次三期研究都宣告失败。因为当疾病一旦恶化时,该种药物的疗效就会大大降低。

2013年1月21日讯 /生物谷BIOON/ --Lilly公司正在实验中的药物solanezumab可能有望治疗阿尔兹海默病,这种药物能够清除淀粉样蛋白,这是一种在阿尔兹海默病患者大脑细胞中广泛存在的蛋白质。但是截止2012年,这种药物的两次三期研究都宣告失败。因为当疾病一旦恶化时,该种药物的疗效就会大大降低。

如今,由于公司获得National Institute on Aging的资助,将再次对这种药物进行研究。如今美国大约有500万老年人饱受阿尔兹海默病的折磨。许多巨头都曾投入巨资研究相关药物,如Big Pharma、Pfizer、Johnson & Johnson等公司,但都以失败告终。(生物谷Bioon.com)

详细英文报道:

Eli Lilly's ($LLY) solanezumab has secured an endorsement from Alzheimer's researchers, who will study the experimental drug as a preventive therapy against the memory-robbing disease in patients before symptoms emerge.

Lilly last year revealed that it would revive its own efforts to develop the amyloid drug, which failed in a pair of Phase III studies last year despite showing signs of efficacy in patients with mild disease. Now the drug has a new lease on life with the help of the so-called A4 study, which has won funding from the NIH's National Institute on Aging.

The going theory is that drugs that clear amyloid--a hallmark of Alzheimer's--don't work once the disease advances. In the new study, investigators want to give sola another shot. The study aims to focus on slowing memory decline by 30%, targeting patients between ages 70 and 85 with early markers for the disease but no symptoms, Reuters reported. Led by Dr. Reisa Sperling from Brigham & Women's Hospital in Boston, the 1,000-patient study is expected to take years and yield final results in 2018.

New treatments can't come fast enough for the more than 5 million Americans suffering from Alzheimer's disease, which health officials and policymakers have flagged as a costly threat to the aging U.S. population. Offering very little help, Big Pharma's gambles on amyloid-blocking drugs have ended in big losses, including Pfizer ($PFE) and Johnson & Johnson's ($JNJ) failed Phase III trials for "bapi" last year. But Roche's ($RHHBY) Genentech, Lilly and others are banking on drugs to succeed as preventive therapies.

We'll see how these players fare with their bold bets, but apparently not for 5 years or so as far as the A4 study is concerned.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->